Application of hUC-MSCs in Treating Acute Lung Injury: a Single Center Prospective Clinical Research
NCT ID: NCT04951882
Last Updated: 2021-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
30 participants
INTERVENTIONAL
2021-06-09
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury
NCT02444455
Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS
NCT03608592
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome
NCT05983627
Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies
NCT02804945
Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome
NCT03818854
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
hUC-MSCs treatment
Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.
human derived umbilical cord derived mesenchymal stem cells
intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
non-cell therapy
Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
human derived umbilical cord derived mesenchymal stem cells
intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2.Age ≥18 years, ≤65 years
* 3.200\<PaO2/FiO2 ≤ 300
* 4.Chest X-ray/chest CT : infiltrates of both lungs
* 5.Need assisted ventilation (ventilation or high flow oxygen therapy)
* 6.No left heart failure, pulmonary edema
* 7.Agree to participate and signe an informed consent
Exclusion Criteria
* 2.Patients receiving extracorporeal membrane oxygenation support therapy(ECMO),high frequency oscillatory ventilation
* 3.History of HIV, malignant tumors, or impaired immune function
* 4.Patients accepted major surgery in the past 14 days (such as tumor removal, thoracotomy, heart surgery, abdominal surgery, intracranial surgery, or surgery for more than 3 hours, etc.)
* 5.Pregnancy
* 6.Have a serious concomitant disease
* 7.Unable to follow-up
* 8.History of severe allergic reactions or allergy to saline and serum
* 9.Already participated in another clinical study within 12 weeks
* 10.Pulmonary edema caused by other underlying diseases
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SAHZU
Hanzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-592
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.